CNAT: Conatus Pharmaceuticals Inc. - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

Conatus Pharmaceuticals Inc.

NASDAQ:CNAT

SummaryFactSheetFinancial
Notice
Stock data is unavailable or the company’s delisted.
Price
$5.56
Loss Chance
58.0%
1.56JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Related
AbbVie
NYSE:ABBV
6.05
$201.55
104.12%
Alexion Pharmaceuticals
NASDAQ:ALXN
6.89
$182.50
52.20%
Biogen
NASDAQ:BIIB
5.83
$193.45
12.40%
BioSpecifics Technologies Corp.
NASDAQ:BSTC
5.84
$88.53
68.60%
China Biologic Products Holdings
NASDAQ:CBPO
6.17
$119.99
95.57%
Jitta Factors
Growth Opportunity (30)
Recent Business Performance (36)
Financial Strength (32)
Return to Shareholders (0)
Competitive Advantage (14)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
1.56
100.00%
2.43
474.05%
2.43
474.05%
6.89
52.20%
6.17
95.57%
COMPANY DESCRIPTION
As of May 26, 2020, Conatus Pharmaceuticals Inc. was acquired by Histogen Inc., in a reverse merger transaction. Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.
www.conatuspharma.com
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.